DBV Technologies S.A. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 14, 2018, reports the full-year 2017 financial results for DBV Technologies S.A., a biopharmaceutical company developing epicutaneous immunotherapy (EPIT) for food allergies. The company's primary candidates include Viaskin Peanut and Viaskin Milk. Audit procedures for the 2017 consolidated financial statements were completed by statutory auditors.
Key Financial Metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Cash and Cash Equivalents (Dec 31) | €137.9 million | €256.5 million |
| Operating Income | €11.9 million | €9.1 million |
| Research & Development Expenses | €105.2 million | €78.8 million |
| Sales & Marketing Expenses | €15.8 million | €11.3 million |
| General & Administrative Expenses | €35.8 million | €35.0 million |
| Net Loss | €147.7 million | €114.5 million |
| Loss Per Share | €(5.97) | €(4.68) |
Liquidity: Cash reserves decreased by €118.6 million year-over-year. The filing text does not provide specific figures for total debt or operating cash flow.
Material Changes
- Operating Income: Increased 31.1% to €11.9 million, driven primarily by the Research Tax Credit (Crédit Impôt Recherche) and revenue from the May 2016 collaboration with Nestlé Health Science.
- R&D Expenses: Increased 33.5% (€26.4 million) due to costs for Phase III (Viaskin Peanut) and Phase II (Viaskin Milk) clinical trials and increased personnel.
- Sales & Marketing: Increased 40.3% (€4.5 million) reflecting higher U.S. headcount and expenses related to the potential North American launch of Viaskin Peanut.
- Net Loss: Widened to €147.7 million from €114.5 million, reflecting increased operational expenditures.
Outlook, Risks, and Commentary
Management commentary highlights the progression of clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis. The filing notes that the company is dedicated to transforming care for food allergic patients where no approved treatments currently exist. No specific forward-looking financial guidance or quantitative risk factors were detailed in this press release summary.
Investor Verification Checklist
- Verify the sustainability of the Research Tax Credit contribution to operating income.
- Confirm the timeline and budget requirements for the ongoing Phase III and Phase II clinical trials.
- Assess the cash burn rate given the €118.6 million decrease in cash reserves.
- Review the terms and revenue recognition status of the Nestlé Health Science collaboration agreement.
- Monitor regulatory milestones for Viaskin Peanut and Viaskin Milk approvals.